



Practitioner's Docket No. MPI01-047P1RNM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kapeller Libermann, Rosana et al.
Application No.: 10/077,130 Group No.: 1652
Filed: February 15, 2002 Examiner: Maryam Monshipouri
For: 59079 AND 12599, PROTEIN KINASE FAMILY MEMBERS AND USES
THEREFOR

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ASSOCIATE POWER OF ATTORNEY

Dear Sir:

The undersigned attorney has the power of attorney in the subject application. She hereby grants an associate power to:

Mario Cloutier
Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, MA 02139

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: July 27, 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

As demonstrated by Appendix A (submitted herewith), Mario Cloutier has passed the Patent Bar Examination and has been granted limited recognition under 37 C.F.R. §10.9(b). Please continue to forward all written and telephonic communications to Jean M. Silveri at the address and telephone number listed below.


Entry of the remarks made herein is respectfully requested.

July 27, 2004

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Jean M. Silveri


Registration No. 39,030

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820




**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR, 10.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 1, 2005



Harry I. Moatz
Director of Enrollment and Discipline



**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR 10.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 1, 2005

Harry I. Moatz
Director of Enrollment and Discipline